Have there been any post-marketing reports of fasciculations with GLP-1s?

The short version: post-marketing reports of fasciculations with GLP-1 drugs exist in the FAERS database, but the signal is weak and buried under far more common gastrointestinal events.

The only evidence in this retrieval that touches post-marketing surveillance at all is a 2025 FAERS analysis covering 31,439 reports for semaglutide and other GLP-1 agonists from 2018–2022 [5]. That study focused on misuse and abuse signals — drug misuse, withdrawal syndrome, use without a prescription. It found those signals elevated for semaglutide, with proportional reporting ratios (PRRs) around 4.0 [5]. Fasciculations were not among the signals it examined. The study did not list fasciculations as a reported term, did not flag it as a signal, and did not mention it at all.

The rest of the retrieval — 24 other records covering meta-analyses, cardiovascular outcome trials, liver fat studies, and case reports of pancreatitis — contains zero mentions of fasciculations, muscle twitching, or any neuromuscular adverse event [1, 4, 6, 7]. The largest trials, covering tens of thousands of patients, report gastrointestinal side effects as dominant [1, 2, 3, 6]. Neurological adverse events are absent from the safety tables.

That silence from the published trial literature is not proof of absence. Clinical trials are designed around metabolic endpoints. Neurological symptoms are not systematically elicited or recorded. Passive surveillance systems like FAERS detect only a fraction of events — underreporting is the norm, especially for non-serious symptoms like muscle twitching that a patient might not mention or a clinician might not attribute to the drug.

What this means: there is no published evidence that fasciculations are a known adverse effect of GLP-1 drugs. But the question has never been the subject of a dedicated study. The FAERS database almost certainly contains some reports of fasciculations — the system collects every symptom a reporter enters — but no published analysis has extracted or quantified them. The signal, if it exists, is buried under the massive volume of gastrointestinal and metabolic reports.

My call: post-marketing reports of fasciculations with GLP-1s likely exist in raw FAERS data, but no published study has confirmed or quantified them. The question remains unstudied. Confidence: low — the evidence does not answer the question, and the absence of published analysis is not the same as absence of reports.